Medtronic announced the U.S. market launch of the first-of-its-kind mySentry™ Remote Glucose Monitor, which allows a parent or caregiver to monitor from another room a patient’s MiniMed Paradigm® REAL-Time Revel™ System. The remote glucose monitor also marks the launch of a new category of Connected Care solutions that will provide...
Category: Products & Tech
Medtronic announced the U.S. market launch of the first-of-its-kind mySentry™ Remote Glucose Monitor, which allows a parent or caregiver to monitor from another room a patient’s MiniMed Paradigm® REAL-Time Revel™ System. The remote glucose monitor also marks the launch of a new category of Connected Care solutions that will provide...
Currently, there are no safe and effective drugs on the market for treating gastroparesis...
I’ve been having some troubles with my pump. Some of the problems are my fault, like forgetting to resume the pump after suspending it for a shower,…
The new year holds promise for better (and smaller!) diabetes devices. Take a look at our favorite up-and-coming products...
Since its recent commercial launch, the Spring Universal Infusion Set has been particularly well received by parents of children with type 1 diabetes. Specifically, the following features were highly favored: the automatic all-in-one inserter (which gives young patients the independence to do their own site changes), the lightning-fast needle insertion...
Let’s say your blood glucose is low. Would the built in safety controls of the car ever take over and force you to pull over?
JDRF-funded researchers have begun enrolling adult patients with type 1 diabetes in the REMOVAL study, to test whether metformin-a drug commonly used to treat type 2 diabetes-could help prevent or reduce the risk of cardiovascular complications in people with type 1 diabetes...
A study released by Novo Nordisk at the International Diabetes Federation (IDF) 21st World Diabetes Congress in Dubai has found that the combination insulin degludec/insulin aspart, currently being developed, significantly reduced hypoglycemia in type 1 diabetes and type 2 diabetes patients...
Sanofi announced positive results from the Gel Duo 1 study of it's investigational GLP-1 agonist, Lyxumia (lixisenatide) in the treatment of type 2 diabetes patients. The results show that patients with type 2 diabetes uncontrolled on oral anti-diabetics (OADs) – mainly metformin - significantly reduced their HbA1c levels when...